Why the right software is key to efficient trial design
Facing delays and inefficiencies in clinical trial design? Learn how the right software can solve key challenges and improve outcomes.
- Latest Posts
In Depth 17 Feb 2025
Biotech’s legal storm: Why securities class action lawsuits are surging
Find out about what’s behind the increase of securities class action lawsuits in the biotech industry and how to prevent them.
Podcast 14 Feb 2025
Reversing cancer mechanisms to fight back against solid tumors
This week, we have a conversation with Catalym’s Eugen Leo about Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15.
Best in Biotech 13 Feb 2025
Seven companies using metabolomics to decode biology
Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.
News and Trends 13 Feb 2025
DeepMind AlphaFold’s alumnus raises $40m for Latent Labs, a new AI biotech startup
Find out about a new AI-driven company that emerges from stealth today to create novel protein – Latent Labs.
In Depth 12 Feb 2025
Dendritic cell therapy: Diakonos, Northwest Biotherapeutics and Mendus push ahead with next-generation candidates
Find out about the field of dendritic cell therapy, as several companies attempt to bring next-generation candidates through the clinic.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 11 Feb 2025
12 ways biotechnology makes the world more sustainable
Biotech companies are turning to biology for solutions to make all aspects of our lives more sustainable for the environment.
In Depth 10 Feb 2025
Monoclonal antibodies: are they the key to treating Alzheimer’s disease?
A major stride in treating Alzheimer’s disease has been the development of monoclonal antibodies.
Partnering 2030: FME Industries Report
Download Inpart’s new report to discover key challenges in the Food, Material, and Electromechanical (FME) industries, the best channels for sourcing new partners, and a ranking of the top companies in industry-academia partnerships.
Podcast 7 Feb 2025
Targeting the dark genome to develop new therapies to fight obesity
This week, our podcast guest is Samir Ounzain, CEO of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’
News and Trends 6 Feb 2025
Top biotech deals of January 2025
January 2025 kicked off in full swing with several biotech deals in the biopharma industry.
In Depth 5 Feb 2025
Needle-free vaccines: Micron Biomedical, Vaxxas, and IntegriMedical bring their new technologies to patients
Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in this space.
ADVERTISEMENT
